Healthcare [ 5/13 ] | Drug Manufacturers - Specialty & Generic [ 54/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 21, 24 | -1.22 Increased by +19.21% | 0.04 Decreased by -3.15 K% |
| Nov 29, 23 | -0.82 Decreased by -2.27 K% | -0.07 Decreased by -1.07 K% |
| Aug 30, 23 | -0.14 Increased by +81.08% | -0.14 |
| May 19, 23 | -1.24 Increased by +61.85% | - |
| Mar 1, 23 | -1.51 Decreased by -1.09 K% | - |
| Nov 15, 22 | -0.03 Decreased by -198.3% | - |
| Aug 31, 22 | -0.74 Decreased by -10.18 K% | - |
| May 16, 22 | -3.25 Decreased by -1.54 K% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 53.39 M Increased by +123.78% | -276.56 M Increased by +13.71% | Decreased by -517.99% Increased by +61.44% |
| Sep 30, 23 | 17.79 M Decreased by -6.63% | -188.32 M Decreased by -2.09 K% | Decreased by -1.06 K% Decreased by -2.24 K% |
| Jun 30, 23 | 4.39 M Decreased by -88.93% | 189.33 M Increased by +276.13% | Increased by +4.31 K% Increased by +1.69 K% |
| Mar 31, 23 | 15.86 M Increased by +3.41 K% | -276.18 M Decreased by -258.77% | Decreased by -1.74 K% Increased by +89.78% |
| Dec 31, 22 | 23.86 M Decreased by -31.37% | -320.51 M Decreased by -226.3% | Decreased by -1.34 K% Decreased by -284.04% |
| Sep 30, 22 | 19.05 M Increased by +3.45 K% | -8.6 M Increased by +89.42% | Decreased by -45.15% Increased by +99.7% |
| Jun 30, 22 | 39.67 M Increased by +331.48% | -107.49 M Decreased by -323.6% | Decreased by -270.99% Increased by +1.83% |
| Mar 31, 22 | 452 K Decreased by -95.08% | -76.98 M Decreased by -203.35% | Decreased by -17.03 K% Decreased by -6.07 K% |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.